Taysha Gene Therapies (TSHA) Net Income towards Common Stockholders (2020 - 2026)

Taysha Gene Therapies has disclosed Net Income towards Common Stockholders across 7 years of filings, most recently posting -$42.4 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$42.4 million, down 96.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$129.9 million (down 49.69% YoY), and the FY2025 annual result was -$109.0 million, down 22.06% from the prior year.
• Net Income towards Common Stockholders came in at -$42.4 million for Q1 2026 at Taysha Gene Therapies, down from -$27.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $47.7 million in Q4 2023 to a low of -$117.1 million in Q3 2023.
• The 5-year median for Net Income towards Common Stockholders is -$26.5 million (2022), against an average of -$30.5 million.
• Peak annual rise in Net Income towards Common Stockholders reached 186.68% in 2023, while the deepest fall reached 341.39% in 2023.
• Taysha Gene Therapies' Net Income towards Common Stockholders stood at -$55.1 million in 2022, then surged by 186.68% to $47.7 million in 2023, then plunged by 139.35% to -$18.8 million in 2024, then slumped by 48.26% to -$27.9 million in 2025, then slumped by 52.27% to -$42.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$42.4 million (Q1 2026), -$27.9 million (Q4 2025), and -$32.7 million (Q3 2025), per Business Quant data.